Basic/Clinical Science Session
Clinical Trials in Pediatric CKD: Trial with SGLT2 Inhibitors?
November 02, 2023 | 02:00 PM - 04:00 PM
Location: Room 108, Pennsylvania Convention Center
SGLT2 inhibitors are a class of drugs that have recently been shown to be effective in slowing the progression of kidney diseases in adults with and without diabetes. The majority of clinical trials have been conducted in adults. This session focuses on the outcomes of clinical trials in adults, as well as obstacles in designing a pediatric clinical trial and a conceptual model for a trial in children. A family's perspective on CKD is also shared.
ASN thanks the Kidney Health Initiative for assistance with this session.
- Describe the effects of SGLT2 inhibitors on the kidneys and the outcomes of clinical trials in adults thus far
- Summarize the various hurdles involved in designing and implementing clinical trials in pediatrics and available solutions
- Develop a conceptual model for a pediatric clinical trial
- Explore a family's perspective on CKD
- Pediatric Nephrology
- CKD Non-Dialysis
- Designing Trials in Pediatric CKD: Hurdles and Solutions
02:00 PM - 02:30 PM
- Journey Through CKD: A Family's Perspective
02:30 PM - 03:00 PM
- SGLT2 Inhibitors and Kidneys: What We Know So Far
03:00 PM - 03:30 PM
- Conceptual Model for Pediatric Trials: SGLT2 Inhibitors in Children with CKD
03:30 PM - 04:00 PM